Risk of Parkinson disease in diabetes mellitus: An updated meta-analysis of population-based cohort studies

Medicine (United States)

Volumn 95, Issue 18, 2016, Pages e3549-

  Yue, Xuejing ^a   Li, Hehua ^b   Yan, Haiqing ^b   Zhang, Ping ^b   Chang, Li ^b   Li, Tong ^b  

^a XINXIANG MEDICAL UNIVERSITY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF XINXIANG MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

COHORT ANALYSIS; DIABETES MELLITUS; DISEASE ASSOCIATION; EVIDENCE BASED PRACTICE; HUMAN; PARKINSON DISEASE; POPULATION RESEARCH; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; DIABETES COMPLICATIONS; FEMALE; MALE; META ANALYSIS; RISK;

DIABETES COMPLICATIONS; FEMALE; HUMANS; MALE; PARKINSON DISEASE; RISK; RISK FACTORS;

EID: 84969862314     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000003549     Document Type: Review

References (46)

1. Ludovico O, Carella M, Bisceglia L, et al. Identification and clinical characterization of adult patients with multigenerational diabetes mellitus. PloS One. 2015;10:e0135855.
2. Glabe CG. Common mechanisms of amyloid oligomer pathogenesis in degenerative disease. Neurobiol Aging. 2006;27:570-575.
3. Santiago JA, Potashkin JA. Shared dysregulated pathways lead to Parkinson's disease and diabetes. Trends Mol Med. 2013;19: 176-186.
4. Arvanitakis Z, Wilson RS, Bienias JL, et al. Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function. Arch Neurol. 2004;61:661-666.
5. Peila R, Rodriguez BL, Launer LJ. Type 2 diabetes, apoe gene, and the risk for dementia and related pathologies the honolulu-asia aging study. Diabetes. 2002;51:1256-1262.
6. Association AD, Neurology AAo. Report and recommendations of the San Antonio conference on diabetic neuropathy. Diabetes Care. 1988;11:592-597.
7. Cereda E, Barichella M, Pedrolli C, et al. Diabetes and risk of Parkinson's disease: a systematic review and meta-analysis. Diabetes Care. 2011;34:2614-2623.
8. Lu L, Fu DL, Li HQ, et al. Diabetes and risk of Parkinson's disease: an updated meta-analysis of case-control studies. PloS One. 2014;9:e85781.
9. Becker C, Brobert GP, Johansson S, et al. Diabetes in patients with idiopathic Parkinson's disease. Diabetes Care. 2008;31:1808-1812.
10. D'Amelio M, Ragonese P, Callari G, et al. Diabetes preceDing Parkinson's disease onset. A case-control study. Parkinsonism Relat Disord. 2009;15:660-664.
11. Herishanu YO, Medvedovski M, Goldsmith JR, et al. A case-control study of Parkinson's disease in urban population of southern Israel. Can J Neurol Sci. 2001;28:144-147.
12. Ho SC, Woo J, Lee CM. Epidemiologic study of Parkinson's disease in Hong Kong. Neurology. 1989;39:1314-11314.
13. Kessler II. Epidemiologic studies of Parkinson's disease: III. A community-based survey. Am J Epidemiol. 1972;96:242-254.
14. Leibson CL, Maraganore DM, Bower JH, et al. Comorbid conditions associated with Parkinson's disease: a population-based study. Mov Disord. 2006;21:446-455.
15. Miyake Y, Tanaka K, Fukushima W, et al. Case-control study of risk of Parkinson's disease in relation to hypertension, hypercholesterolemia, and diabetes in Japan. J Neurol Sci. 2010;293: 82-86.
16. Morano A, Jimenez-Jimenez FJ, Molina JA, et al. Risk-factors for Parkinson's disease: case-control study in the province of caceres, Spain. Acta Neurol Scan. 1994;89:164-170.
17. Powers KM, Smith-Weller T, Franklin GM, et al. Diabetes, smoking, and other medical conditions in relation to Parkinson's disease risk. Parkinsonism Relat Disord. 2006;12:185-189.
18. Rugbjerg K, Friis S, Ritz B, et al. Autoimmune disease and risk for Parkinson disease a population-based case-control study. Neurology. 2009;73:1462-1468.
19. Savica R, Grossardt BR, Ahlskog JE, et al. Metabolic markers or conditions preceDing Parkinson's disease: a case-control study. Mov Disord. 2012;27:974-979.
20. Schernhammer E, Hansen J, Rugbjerg K, et al. Diabetes and the risk of developing Parkinson's disease in Denmark. Diabetes Care. 2011;34:1102-1108.
21. Scigliano G, Musicco M, Soliveri P, et al. Reduced risk factors for vascular disorders in Parkinson disease patients a case-control study. Stroke. 2006;37:1184-1188.
22. Skeie GO, Muller B, Haugarvoll K, et al. Parkinson disease: associated disorders in the Norwegian population based incident ParkWest study. Parkinsonism Relat Disord. 2013;19:53-55.
23. De Pablo-Fernández E, Sierra-Hidalgo F, Sánchez-Ferro A, et al. Diabetes and risk of Parkinson's disease: evidence from the population-based NEDICES study. Mov Disord. 2014;29:S542.
24. Driver JA, Smith A, Buring JE, et al. Prospective cohort study of type 2 diabetes and the risk of Parkinson's disease. Diabetes Care. 2008;31:2003-2005.
25. Hu G, Jousilahti P, Bidel S, et al. Type 2 diabetes and the risk of Parkinson's disease. Diabetes Care. 2007;30:842-847.
26. Llorens-Arenas R, Rodriguez-Violante M, Cervantes-Arriaga A, et al. Risk of Parkinson's disease onset in patients with diabetes, hypertension, dyslipidemia and obesity in Mexican population. Mov Disord. 2015;30:S40-S41.
27. Palacios N, Gao X, McCullough ML, et al. Obesity, diabetes, and risk of Parkinson's disease. Mov Disord. 2011;26:2253-2259.
28. Palacios N, McCullough M, Jacobs E, et al. Obesity, diabetes and risk of Parkinson disease in a large prospective cohort of men and women. Neuroepidemiology. 2009;33:70-71.
29. Simon KC, Chen H, Schwarzschild M, et al. Hypertension, hypercholesterolemia, diabetes, and risk of Parkinson disease. Neurology. 2007;69:1688-1695.
30. Sun Y, Chang YH, Chen HF, et al. Risk of Parkinson disease onset in patients with diabetes: a 9-year population-based cohort study with age and sex stratifications. Diabetes Care. 2012;35:1047-1049.
31. Xu Q, Park Y, Huang X, et al. Diabetes and risk of Parkinson's disease. Diabetes Care. 2011;34:910-915.
32. Quigley J, Thompson J, Halfpenny N, et al. Critical appraisal of non-randomized controlled studies-a review of recommended and commonly used tools. Value Health. 2014:17.
33. Lan KG, Pinheiro J. Combined estimation of treatment effects under a discrete random effects model. Stat Biosci. 2012;4:235-244.
34. Higgins JP, Thompson SG. Quantifying heterogeneity in a metaanalysis. Stat Med. 2002;21:1539-1558.
35. Egger M, Smith GD, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629-634.
36. Peters JL, Sutton AJ, Jones DR, et al. Performance of the trim and fill method in the presence of publication bias and between-study heterogeneity. Stat Med. 2007;26:4544-4562.
37. Pradhan A. Obesity, metabolic syndrome, and type 2 diabetes: inflammatory basis of glucose metabolic disorders. Nutr Rev. 2007;65:S152.
38. Chen H, O'Reilly EJ, Schwarzschild MA, et al. Peripheral inflammatory biomarkers and risk of Parkinson's disease. Am J Epidemiol. 2008;167:90-95.
39. Sandyk R. The relationship between diabetes mellitus and Parkinson's disease. Int J Neurosci. 1993;69:125-130.
40. Friederich M, Hansell P, Palm F. Diabetes, oxidative stress, nitric oxide and mitochondria function. Curr Diabetes Rev. 2009;5:120-144.
41. Henchcliffe C, Beal MF. Mitochondrial biology and oxidative stress in Parkinson disease pathogenesis. Nat Clin Pract Neurol. 2008;4:600-609.
42. Schernhammer E, Hansen J, Rugbjerg K, et al. Diabetes and the risk of developing Parkinson's disease in Denmark. Diabetes Care. 2011;34:1102-1108.
43. Craft S, Watson GS. Insulin and neurodegenerative disease: shared and specific mechanisms. Lancet Neurol. 2004;3:169-178.
44. Giuntini M, Baldacci F, Del Prete E, et al. Diabetes is associated with postural and cognitive domains in Parkinson's disease. Results from a single-center study. Parkinsonism Relat Disord. 2014;6:671-672.
45. Bohnen NI, Kotagal V, Müller ML, et al. Diabetes mellitus is independently associated with more severe cognitive impairment in Parkinson disease. Parkinsonism Relat Disord. 2014;20:1394-1398.
46. Nassar NN, Al-Shorbagy MY, Arab HH, et al. Saxagliptin: a novel antiparkinsonian approach. Neuropharmacology. 2015;89:308-317.